Stock Comparison

LLY vs SRPT

Eli Lilly and Co vs Sarepta Therapeutics Inc

The Verdict

SRPT takes this one.

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Winner

SRPT

Sarepta Therapeutics Inc

6.8

out of 10

Solid Pick

Head-to-Head

$965.0B

Market Cap

$1.9B

52.6

P/E Ratio

29.0

N/A

Profit Margin

3.0%

N/A

Return on Equity

4.9%

N/A

Debt-to-Equity

0.7

Moderate

Overall Risk

Moderate

0.5

DVR Score

6.8

The Deep Dive

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

SRPT6.8/10

Score Change Explanation: The previous analysis (2026-04-05) highlighted "persistent commercial execution issues for Elevidys, reflected in Q4 2025's wider-than-expected loss and reduced 2026 revenue guidance." The Q1 2026 earnings, reported on May 6, 2026, represent a material positive change. Sarepta reported a significant swing to GAAP operating income of $358.4 million and GAAP net income of $...

Full SRPT Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.